Twist Bioscience Acquires Abveris
November 22, 2021
Twist Bioscience entered into a definitive agreement to acquire Abveris (formerly AbX Biologics), an in vivo antibody discovery services company, for up to $190 million. The deal (approximately $150 million at closing in Twist common stock and up to $40 million contingent stock consideration plus limited cash) is intended to combine Abveris's mouse-based discovery platform with Twist's humanization and antibody engineering capabilities to broaden Twist's antibody discovery and biopharma services.
- Buyers
- Twist Bioscience Corporation
- Targets
- Abveris (formerly AbX Biologics, Inc.)
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
AVS Bio Acquires ImmunoPrecise Antibodies (Europe) B.V.
August 6, 2025
Biotechnology
AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies (Europe) B.V., a carve-out from ImmunoPrecise Antibodies Ltd. The acquisition expands AVS Bio's European footprint and adds antibody discovery, recombinant protein expression, and organoid growth factor development capabilities to its biologics services platform.
-
BioNTech Acquires Biotheus
February 3, 2025
Biotechnology
BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.
-
Biogen Acquires Human Immunology Biosciences for up to $1.8B
May 22, 2024
Biotechnology
Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.
-
Eli Lilly Acquires Versanis Bio
July 14, 2023
Biotechnology
Eli Lilly has entered into a definitive agreement to acquire Versanis Bio, a private clinical-stage biopharmaceutical company developing bimagrumab for cardiometabolic diseases and obesity. The deal could deliver up to $1.925 billion to Versanis shareholders and is intended to combine Versanis’ activin/myostatin biology expertise with Lilly’s incretin portfolio to advance combination treatments for obesity and related cardiometabolic conditions.
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.